Scientific Industries, Inc.: Scientific Industries Reports Second Quarter Fiscal 2026 Results
Scientific Industries, Inc. (OTCQB: SCND) reported fiscal 2026 Q2 results for the three and six months ended June 30, 2026. Net revenues rose to $1.47M and $2.70M, up 36% and 33% year over year. Gross profit increased, operating expenses fell 13% and 13%. Net loss was $1.23M and $2.82M. Cash and investments totaled $4.55M.
How this was made
The 30-second read
Why it matters
Q2 FY2026 results provide fresh financial datapoints (revenue, gross margin, operating expense trend) and forward operational milestones (VIVID ONE shipping in September 2026, AI model launch planned for Q1 2027).
Market read
Traders can reassess near-term expectations for recurring VIVID revenue and DOTS platform adoption using the reported revenue growth, margin expansion, and cost reductions, despite ongoing net losses.
What to watch
The release mentions a recast for discontinued operations and provides no segment-level cash flow or guidance, so traders may discount the durability of the margin gains.
Background
Scientific Industries develops DOTS bioprocessing sensing systems and VIVID vision-based pill counters, and it is transitioning toward expanded VIVID subscription plans.
Ticker impact
Scientific Industries reported Q2 FY2026 results, with net revenues up 36% YoY and gross margin improving to 42.3%.
Near-term bias modestly positive, with follow-through dependent on whether recurring VIVID subscription shipping and DOTS platform traction convert into sustained profitability.
Revenue and gross margin improved materially, operating expenses declined, and management highlighted expanded VIVID subscription plans and DOTS progress. However, net loss widened vs prior-year per-share, limiting upside conviction.
Market effects
Supports the narrative that bioprocessing instrumentation and lab automation vendors can grow via platform products and recurring subscriptions.
No clear regional read-through beyond small-cap OTC liquidity.
Limited global impact; primarily relevant to niche lab automation and bioprocessing equipment investors.
Counterpoint
Margin improvement may be driven by product mix or timing, and continued net losses suggest cash burn risk remains until DOTS and VIVID scale.
Key entities
- companyScientific Industries, Inc.
OTCQB-listed developer of DOTS bioprocessing systems and VIVID pill counters; reported Q2 FY2026 results.
- executiveHelena Santos
CEO, cited progress in VIVID subscription plans and machine learning model development.
- executiveJohn Moore
Chairman, discussed DOTS pH sensor insights and customer trial progress.
